Survival Gains Seen With Assignment to Experimental Group in Cancer Trials
By Elana Gotkine HealthDay Reporter
TUESDAY, April 30, 2024 -- For patients with solid tumors, assignment to an experimental group in trials of investigational drugs yields significant survival gains, according to a review published online April 30 in the Annuals of Internal Medicine.
Renata Iskander, from McGill University in Montreal, and colleagues estimated progression-free survival and overall survival advantage of assignment to experimental groups in randomized trials of investigational drugs for six solid tumors. A total of 128 trials with 141 comparisons of a new drug and comparator were included in the sample, with 47,050 patients.
The researchers found that the pooled hazard ratio was 0.80 for progression-free survival, indicating significant benefit for patients in experimental groups and corresponding to a median progression-free survival advantage of 1.25 months. For overall survival, the pooled hazard ratio was 0.92, corresponding to a 1.18-month increase in survival. The absolute risk for a serious adverse event was 29.56 percent for comparator group patients compared with a 7.40 percent increase in risk for patients in experimental groups.
"Our findings provide a reassuring picture of current practices in drug regulation and research and can also help inform decisions about patient referral to trials, research policy, and consent discussions," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
American Society of Clinical Oncology, May 30-June 4
The annual meeting of the American Society of Clinical Oncology was held from May 30 to June 4 in Chicago and hosted more than 34,000 participants from around the world, including...
New Clinical Score Can Predict Immune Checkpoint Blockade Response
MONDAY, June 10, 2024 -- For patients with cancer, a novel clinical score using a six-feature regression model can predict immune checkpoint blockade (ICB) response probability...
ASCO: Germline Variation Does Not Predict Taxane-Induced Peripheral Neuropathy
FRIDAY, June 7, 2024 -- Germline variation does not predict the risk of taxane-induced peripheral neuropathy (TIPN) in Black women receiving paclitaxel (once weekly) or docetaxel...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.